{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-055953","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.826619+00:00","generated_at":"2026-05-16T13:50:12.886068+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Senti Bio reports SENTI-202 Phase 1 data: 50% ORR, 42% CR/CRh at RP2D; receives FDA RMAT designation","bullets":["In 18 evaluable R/R AML patients, SENTI-202 achieved 50% ORR and 42% CR/CRh at RP2D; 100% of CRs MRD negative and median duration of CR 7.6 months.","SENTI-202 was well-tolerated with no DLTs, no drug-related SAEs, and most AEs hematologic consistent with lymphodepletion.","FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202, adding to prior Orphan Drug Designation.","Logic Gate mechanism validated: selective killing of AML blasts/LSCs while sparing healthy hematopoietic stem/progenitor cells.","Company to host investor call Dec 9 at 8 AM ET; SENTI-202 potential for pivotal studies and expansion into newly diagnosed AML, pediatric AML, MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-055953","json":"https://secwatch.observer/filing/0001628280-25-055953.json","markdown":"https://secwatch.observer/filing/0001628280-25-055953.md","text":"https://secwatch.observer/filing/0001628280-25-055953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828025055953/0001628280-25-055953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828025055953/snti-20251209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:50:12.886068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}